BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a California-based global biotechnology company, announced on Wednesday that it has named Alexander Hardy as its new president and chief executive officer.

Hardy is to succeed Jean-Jacques Bienaime, who will retire as chairman and CEO effective 1 December 2023.

Hardy has over 30 years of experience in the global healthcare and biotechnology industries. He has served as the CEO of Genentech and in various senior roles at Roche and in leadership roles at Novartis, PathoGenesis and GSK.